Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients | Zendy

Márcio Nucci | Zendy; Kieren A. Marr | Zendy; Flávio QueirozTelles | Zendy; C. A. S. Martins | Zendy; Plı́nio Trabasso | Zendy; Sílvia Figueiredo Costa | Zendy; J C Voltarelli | Zendy; Arnaldo Lopes Colombo | Zendy; Alexander Imhof | Zendy; Ricardo Pasqüini | Zendy; Ângelo Maiolino | Zendy; A. S. Carmino | Zendy; E. Anaissie | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients

Author(s) -

Márcio Nucci,

Kieren A. Marr,

Flávio QueirozTelles,

C. A. S. Martins,

Plı́nio Trabasso,

Sílvia Figueiredo Costa,

J C Voltarelli,

Arnaldo Lopes Colombo,

Alexander Imhof,

Ricardo Pasqüini,

Ângelo Maiolino,

A. S. Carmino,

E. Anaissie

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/383319

Subject(s) - fusariosis , medicine , hematopoietic stem cell transplantation , transplantation , incidence (geometry) , epidemiology , cumulative incidence , neutropenia , surgery , immunology , chemotherapy , biology , fusarium , physics , horticulture , optics

To characterize the epidemiology and prognostic factors of invasive fusariosis in hematopoietic stem cell transplant (HSCT) recipients, the records of HSCT recipients from 9 hospitals (7 in Brazil and 2 in the United States) were retrospectively reviewed. Sixty-one cases were identified: 54 in allogeneic HSCT recipients and 7 in autologous HSCT recipients. The incidence of fusariosis among allogeneic HSCT recipients varied between a range of 4.21-5.0 cases per 1000 in human leukocyte antigen (HLA)--matched related transplant recipients to 20.19 cases per 1000 in HLA-mismatched transplant recipients. The median time period between transplantation and diagnosis of fusariosis was 48 days. Among allogeneic HSCT recipients, a trimodal distribution was observed: a first peak before engraftment, a second peak at a median of 62 days after transplantation, and a third peak >1 year after transplantation. The actuarial survival was 13% (median, 13 days). Persistent neutropenia was the single prognostic factor for death identified by multivariate analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research